Orphan Drug vs. Fast Track vs. Breakthrough vs. Rare Pediatric Disease designation: which to pursue, in what order

Pursue Orphan Drug designation first, as soon as you can document US prevalence under 200,000 and a medically plausible mechanism, and file Rare Pediatric Disease designation with it if the disease primarily affects children. Request Fast Track at or shortly after IND acceptance using nonclinical data. Hold Breakthrough Therapy until you have preliminary clinical evidence of substantial improvement. The designations stack, and none changes the approval standard.

What does each designation actually give you?

A designation is a status FDA grants during development. It is not an approval. Orphan Drug designation lives in section 526 of the Federal Food, Drug, and Cosmetic Act, Fast Track and Breakthrough Therapy in section 506, and Rare Pediatric Disease in section 529.

The table draws on section 526 for the orphan test [1], section 527 for exclusivity [2], the Internal Revenue Code for the credit [3], section 506 for the Fast Track and Breakthrough clocks [4], and section 529 for the pediatric definition [5].

When should I file for Orphan Drug designation?

File as early as the evidence allows, which is often before the IND. The statute only requires that the request precede the marketing application [1]. The regulation asks for a specific disease, a documented prevalence estimate or cost-recovery case, and a scientific rationale establishing a medically plausible basis for the drug's use, supported by laboratory, animal, or clinical data [6].

The incentives are real money. Approval of a designated drug for the designated condition blocks approval of the same drug for the same use for seven years [2]. Qualified clinical testing expenses earn a 25 percent credit, reduced from 50 percent for tax years beginning after December 31, 2017 [3]. FDA's page lists the user fee exemption alongside these [7].

The prevalence estimate will be scrutinized, and I have seen sponsors stretch a subset definition past what FDA accepts. Exclusivity also has exceptions: FDA may approve a competitor if the holder cannot assure sufficient supply, if the holder consents, or if the competitor shows clinical superiority in efficacy, safety, or a major contribution to patient care [2].

Is the Rare Pediatric Disease voucher still available in 2026?

Yes, as of this writing. The program had been set to stop awarding vouchers after September 30, 2026. FDA's page now states that with enactment of the Consolidated Appropriations Act, 2026 on February 3, 2026, the program sunsets after September 30, 2029, with no separate deadline by which the drug must be designated [8]. The statute's termination clause agrees [5].

A rare pediatric disease is a rare disease whose serious or life-threatening manifestations primarily affect individuals from birth to 18 years [5]. The statute ties the request to the orphan or Fast Track request and gives FDA 60 days to decide [5]. FDA's page allows the request any time before the marketing application [8].

The voucher is the prize. It is awarded at approval, buys a priority review for a different product, and can be sold with no transfer limit [5]. GAO counted 31 vouchers awarded across FDA's programs from fiscal 2009 through 2019, mostly for rare pediatric diseases, 17 of them sold for roughly $67 million to $350 million, and noted that published studies found little or no effect on development decisions, though the developers GAO interviewed described the voucher as one factor among several [9].

The arithmetic for a program at IND today is poor. The voucher requires approval before the sunset, so a product entering first-in-human in 2026 needs approval within about three years. Designation still costs little and signals seriousness to pediatric investigators, so I file it with the orphan request. I do not model voucher proceeds in a base case.

When is Fast Track worth requesting, and when is Breakthrough?

Fast Track fits the IND stage. The criteria are a serious condition plus nonclinical or clinical data showing potential to address an unmet medical need, and the request may be made with or after the IND [11]. FDA answers within 60 days, and the benefits are frequent meetings, written feedback on trial design and biomarkers, rolling review, and priority review eligibility [10]. The 2014 guidance says to request no later than the pre-NDA or pre-BLA meeting [11].

Breakthrough Therapy is a clinical-stage designation. It requires preliminary clinical evidence that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint [12]. FDA weighs the magnitude and importance of the effect and wants requests no later than the end-of-Phase 2 meeting [12]. A product may hold both at once [11].

The payoff is measurable. An analysis of drugs approved from 2006 to 2020, comparing Breakthrough products with FDA-selected comparators, found the designation was associated with 30 percent shorter late-stage development, measured from end-of-Phase 2 meeting to approval [13]. Among 581 novel drug-indication approvals from 2008 to 2021, 34.9 percent used Fast Track and 19.8 percent used Breakthrough, and use of any expedited program rose from 42.3 percent to 74.5 percent [14].

What order did I follow on a live program?

On the first-in-class biologic for a rare pediatric leukemia, the sequence was IND acceptance, Fast Track designation two months later, then first-in-human Phase 1. The request worked because it reused the IND's nonclinical efficacy and safety package rather than generating new data. The 60-day clock gave us FDA's answer before the first patient was dosed.

My general order is orphan designation as soon as the prevalence and mechanism data are defensible, Rare Pediatric Disease designation in the same window, Fast Track at or just after IND acceptance, and Breakthrough only when a clinical dataset exists. For cell and gene therapies, Regenerative Medicine Advanced Therapy designation under section 506(g) is the clinical-stage equivalent, with its own 60-day clock [4].

What can these designations not do?

They do not lower the evidence bar. Approval still requires substantial evidence of effectiveness, and FDA may rescind an expedited designation if the product no longer meets the criteria [11]. They do not make you unusual. In 2024, CDER approved 50 novel drugs; 26 had orphan designation and 33 used one or more expedited programs [15]. A designation list is a floor, not a pitch.

They also do not pay for the trial. The orphan credit applies to qualified clinical testing expenses, not preclinical work [3]. The voucher arrives only with approval. Fast Track and Breakthrough buy FDA attention, which is worth only as much as the questions and plan the sponsor brings to each meeting.

This article is part of the Life Sciences Consulting practice at Hamilton Atlas Group — see the full capability list there.

References

1. Legal Information Institute, Cornell Law School. 21 U.S. Code § 360bb - Designation of drugs for rare diseases or conditions. Cornell Law School, 2026.
2. Legal Information Institute, Cornell Law School. 21 U.S. Code § 360cc - Protection for drugs for rare diseases or conditions. Cornell Law School, 2026.
3. Legal Information Institute, Cornell Law School. 26 U.S. Code § 45C - Clinical testing expenses for certain drugs for rare diseases or conditions. Cornell Law School, 2026.
4. Legal Information Institute, Cornell Law School. 21 U.S. Code § 356 - Expedited approval of drugs for serious or life-threatening diseases or conditions. Cornell Law School, 2026.
5. Legal Information Institute, Cornell Law School. 21 U.S. Code § 360ff - Priority review to encourage treatments for rare pediatric diseases. Cornell Law School, 2026.
6. Legal Information Institute, Cornell Law School. 21 CFR § 316.20 - Content and format of a request for orphan-drug designation. Cornell Law School, 2026.
7. U.S. Food and Drug Administration. Designating an Orphan Product: Drugs and Biological Products. FDA, 2026.
8. U.S. Food and Drug Administration. Rare Pediatric Disease Designation and Priority Review Voucher Programs. FDA, 2026.
9. U.S. Government Accountability Office. Drug Development: FDA's Priority Review Voucher Programs. GAO-20-251, 2020.
10. U.S. Food and Drug Administration. Fast Track. FDA, 2024.
11. U.S. Food and Drug Administration. Expedited Programs for Serious Conditions | Drugs and Biologics. FDA, 2014.
12. U.S. Food and Drug Administration. Breakthrough Therapy. FDA, 2018.
13. Miller KL, Stern AD, Kearsley A, Kao J. FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time. Health Affairs. 2024;43(7):1003-1010.
14. Monge AN, Sigelman DW, Temple RJ, Chahal HS. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021. JAMA Network Open. 2022;5(11):e2239336.
15. U.S. Food and Drug Administration. CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. FDA, 2025.